Alzamend Neuro, Inc. - Common Stock (NQ:ALZN)

1.413 +0.043 (+3.12%)

Delayed Quote Updated: 10:34 AM EDT, Oct 5, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Alzamend Neuro, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 10 11 Next >

EXCLUSIVE: Alzamend Neuro Initiates First Phase 2 Trial Of Lead Program In Healthy Human Participants ↗

May 13, 2025

Alzamend Neuro starts Phase 2 trial of AL001 with novel coil tech to test improved lithium delivery in the brain for multiple mental health conditions.

Via Benzinga

Curious about the stocks that are showing activity after the closing bell on Friday? ↗

May 09, 2025

Let's have a look at what is happening on the US markets after the closing bell on Friday. Below you can find the top gainers and losers in today's after hours session.

Via Chartmill

Alzamend Neuro Partners with QMENTA, to Advance AI-Powered Imaging for its Phase II Clinical Trial of AL001 Study to Take Place at Massachusetts General Hospital

May 07, 2025

From Alzamend Neuro, Inc.

Via GlobeNewswire

EXCLUSIVE: Alzamend Neuro Partners with QMENTA To Advance AI-Powered Imaging For Is Phase 2 Trial Of Lead Program ↗

May 07, 2025

Alzamend Neuro teams up with QMENTA for five AL001 Phase 2 trials at Mass General, targeting Alzheimer's, PTSD, bipolar disorder, and more.

Via Benzinga

Alzamend Neuro Announces Initiation Date of Phase II Clinical Trial of AL001 for Treatment of Alzheimer’s Disease to take Place at Massachusetts General Hospital

March 25, 2025

Head-to-head studies of AL001 versus a marketed lithium carbonate product will be conducted for comparisons of lithium blood and brain/brain-structure pharmacokinetics in Alzheimer’s subjects

From Alzamend Neuro, Inc.

Via GlobeNewswire

Alzamend Neuro Announces Initiation Date of Phase II Clinical Trial of AL001 for Treatment of Major Depressive Disorder to take Place at Massachusetts General Hospital

March 18, 2025

From Alzamend Neuro, Inc.

Via GlobeNewswire

Alzamend Neuro Announces Initiation Date of Phase II Clinical Trial of AL001 for Treatment of Post-Traumatic Stress Disorder to take Place at Massachusetts General Hospital

March 11, 2025

Head-to-head studies of AL001 versus a marketed lithium carbonate product will be conducted for comparisons of lithium blood and brain/brain-structure pharmacokinetics in PTSD subjects

From Alzamend Neuro, Inc.

Via GlobeNewswire

EXCLUSIVE: Alzamend Neuro To Launch Phase 2 Study For Lead Drug For PTSD Patients In Late 2025 To Assess Lithium Delivery Benefits ↗

March 11, 2025

Alzamend Neuro plans a Phase 2 trial of AL001 for PTSD in late 2025, aiming for better lithium delivery, improved safety, and reduced systemic side effects.

Via Benzinga

Alzamend Neuro Announces Initiation Date of Phase II Clinical Trial of AL001 for Treatment of Bipolar Disorder to take Place at Massachusetts General Hospital

March 04, 2025

Head-to-head studies of AL001 versus a marketed lithium carbonate product will be conducted for comparisons of lithium blood and brain/brain-structure pharmacokinetics in Bipolar Disorder subjects

From Alzamend Neuro, Inc.

Via GlobeNewswire

Alzamend Neuro Announces Initiation Date of First Phase II Clinical Trial of AL001 to take Place at Massachusetts General Hospital

February 25, 2025

Head-to-head studies of AL001 versus a marketed lithium carbonate product will be conducted for comparisons of lithium blood and brain/brain-structure pharmacokinetics in healthy human subjects

From Alzamend Neuro, Inc.

Via GlobeNewswire

EXCLUSIVE: Alzamend Neuro To Start First Phase 2 Study For Lead Candidate In 2025 ↗

February 25, 2025

Alzamend Neuro will begin its first Phase 2 trial of AL001 in 2025, using advanced imaging to study lithium distribution and optimize treatment efficacy.

Via Benzinga

Stay updated with the stocks that are on the move in today's pre-market session. ↗

February 19, 2025

As the US market prepares to open on Wednesday, let's get an early glimpse into the pre-market session and identify the stocks leading the pack in terms of gains and losses.

Via Chartmill

Alzamend Neuro Announces Completion of a Novel Head Coil by Tesla for Measuring Brain Structure Lithium Levels in Five Upcoming Phase II Clinical Trials at Massachusetts General Hospital

February 19, 2025

From Alzamend Neuro, Inc.

Via Business Wire

EXCLUSIVE: Alzamend Neuro Says Tesla Dynamic Completes Head Coil To Measure Brain Structure Lithium Levels ↗

February 19, 2025

Alzamend Neuro developed a head coil for high-resolution brain imaging in Phase 2 trials, aiming to optimize lithium dosing for neurological conditions.

Via Benzinga

EXCLUSIVE: Alzamend Neuro Reveals Full Data From Nonclinical Study Of Its Lead Alzheimer's Drug Potential ↗

November 19, 2024

Alzamend Neuro's AL001 study highlights safety and therapeutic potential for Alzheimer's and psychiatric conditions, reducing systemic side effects.

Via Benzinga

Alzamend Neuro to Present at the Sequire Investor Summit

January 15, 2025

From Alzamend Neuro, Inc.

Via Business Wire

Alzamend Neuro Announces Full Data Set from Phase IIA Multiple Ascending Dose Clinical Trial for AL001 Treatment of Dementia Related to Alzheimer’s

October 16, 2024

Alzamend Neuro, Inc. (NASDAQ:ALZN) (“Alzamend”), a clinical-stage biopharmaceutical company focused on developing novel products for the treatment of Alzheimer’s disease

Via PressReach

Alzamend Neuro to Present Non-Clinical Data Update at the Society of Toxicology 2025 Annual Meeting and ToxExpo

December 18, 2024

From Alzamend Neuro, Inc.

Via Business Wire

EXCLUSIVE: Alzamend Neuro Reveals Full Data Set From Multiple Ascending Dose Trial For Lead Candidate For Dementia Related to Alzheimer's ↗

October 16, 2024

Alzamend Neuro completed a Phase 2A study on AL001, identifying a safe lithium dose for Alzheimer's patients. The company plans further trials comparing brain lithium levels in Alzheimer's and other...

Via Benzinga

Alzamend Neuro Regains Compliance with Nasdaq Listing Standards

October 15, 2024

October 15,

Via PressReach

Alzamend Neuro Reports Second Quarter 2025 Financial Results and Provides Update on Clinical Programs

December 12, 2024

From Alzamend Neuro, Inc.

Via Business Wire

Alzamend Neuro CEO Stephan Jackman to Participate in the Maxim Group’s Virtual Healthcare Conference

October 10, 2024

October 10,

Via PressReach

Alzamend Neuro Announces Full Data Set from its Nonclinical Study: Comparing Brain and Plasma Lithium Exposures between AL001 and Lithium Carbonate in Alzheimer’s Transgenic Mice

November 19, 2024

From Alzamend Neuro, Inc.

Via Business Wire

Why Bit Digital Shares Are Trading Higher By Around 11%; Here Are 20 Stocks Moving Premarket ↗

August 20, 2024

Via Benzinga

Alzamend Neuro Announces Full Data Set from Phase IIA Multiple Ascending Dose Clinical Trial for AL001 Treatment of Dementia Related to Alzheimer’s

October 16, 2024

From Alzamend Neuro, Inc.

Via Business Wire

Nvidia, AMD, Alzamend Neuro, Palo Alto Networks, Tesla: Why These 5 Stocks Are On Investors' Radars Today ↗

August 19, 2024

On Monday, major U.S. indices closed in positive territory. The Dow Jones Industrial Average rose 0.6% to finish at 40,896.53.

Via Benzinga

Topics Stocks

Alzamend Neuro Regains Compliance with Nasdaq Listing Standards

October 15, 2024

From Alzamend Neuro, Inc.

Via Business Wire

Nasdaq Surges 150 Points; Sonder Holdings Shares Surge ↗

August 19, 2024

Via Benzinga

Alzamend Neuro CEO Stephan Jackman to Participate in the Maxim Group’s Virtual Healthcare Conference

October 10, 2024

From Alzamend Neuro, Inc.

Via Business Wire

Alzamend Neuro Issues Letter to Stockholders

August 26, 2024

From Alzamend Neuro

Via Business Wire

< Previous 1 2 3 4 5 6 7 8 9 10 11 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.